Close Menu

Breaking News

The firm moved closer to commercializing its lung transplant test, and it was notified by New York State that it could begin testing patient samples using its DTC celiac disease test.

CareDx said it will add XynManagement's products to its digital solutions portfolio and integrate them with current offerings including OTTR.

ViroGates has also validated the instrument for use with its suPARnostic Quick Triage product, which will be included in the reader's test menu.

The Oakland, California-based company will use the funding to speed the manufacturing and commercialization of its dual alcohol and marijuana breathalyzer. 

The firm said that it is working with partners to provide collection devices that can be used at home, making it easier for people to gain access to tests.

The proposed acquisitions follows two deals last month by PreCheck and is aimed at strengthening its point-of-care screening capabilities.

The firm said that it is developing an over-the-counter diagnostic technology to detect mosquito-borne illnesses in minutes instead of days.

The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.

Nasdaq told the company that as of June 30 its shareholder equity does not meet the minimum $2.5 million required for its shares to remain listed on the exchange.

The SuperExtract 32 with the SuperExtract Viral Mag NA Purification kit provides high-quality purification of hepatitis and HIV viral nucleic acid.

The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractor Palmetto for the week of 8/22/2019.

The FDA cleared the system, comprising a blood collection device and associated test to measure long-term glucose levels in patients with diabetes. 

The firm said it will use the funding to invest in research and development that will improve upon its deep shotgun metagenomic sequencing technology.

The Medicare contractor has proposed to cover the non-invasive test for certain kidney and heart transplant patients.

MyCartis said that the new company, Antelope Dx, is developing a home test to diagnose Chlamydia trachomatis and Neisseria gonorrhea.

The drug developer said that the biomarker panel will form the basis of a planned point-of-care test for acute respiratory distress syndrome.

After reviewing more than 100 studies, the panel issued recommendations focused on women with a personal or family history of BRCA1/2-related cancers or high-risk ancestry.

The system is designed to analyze data from routine blood and biochemistry tests to identify immunological abnormalities that indicate high cancer risk.

Trinity Biotech said that the decline in point-of-care revenues reflects lower sales in its two key geographic markets, Africa and the US.

A model combining metabolic biomarkers and sex proved more effective in predicting all-cause mortality than a model based on conventional risk factors.

The partners plan to validate the accuracy, effectiveness, and clinical implications of Group K's MultiNostic liver function test, which is pending FDA clearance.

The revenues come entirely from CGI's discovery services as its divested biopharma services and clinical lab units were considered discontinued operations.

The companies said that they will combine NeuroFlow’s mental health integration platform and Genomind's Professional PGx Express pharmacogenomics service.

Pages